NCT00938899View on ClinicalTrials.gov

TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Hepatitis C
Interventions
DRUG

TMC435350; Placebo

All Listed Sponsors
lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00938899 - TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing | Biotech Hunter | Biotech Hunter